Clinical Trial Update: Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma [NA]

View source ↗

Summary

Completed study evaluating toxicity and antibody responses of a KLH-conjugated bivalent GD2/GD3 vaccine with QS-DG or OPT-821 adjuvants in disease-free AJCC sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• KLH-conjugated bivalent GD2/GD3 vaccine
• OPT-821 adjuvant (OPT-821)
• QS-DG adjuvant (QS-DG)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | NA | Status: COMPLETED | Results posted: 2016-08-10